Abstract
The NMDAR2B subunit is the focus of increasing interest as a therapeutic target in a wide range of CNS pathologies, including acute and chronic pain, stroke and head trauma, drug-induced dyskinesias, and dementias. Due to significant pharmaceutical endeavor, an impressive collection of chemical leads has been developed which target the NR2B subunit, some of which appear to discriminate between closely related subtypes. We now have the benefit of a structural template for the ifenprodil binding site which should further improve future structure activity relationships. A growing appreciation of the likely extrasynaptic localisation of the NR2B receptor subtype and importance of NR2B protein modification, notably tyrosine phosphorylation, may explain its therapeutic importance. The apparent superior preclinical and clinical data for the second and third generation NR2B compounds is likely to reflect subtype selectivity, a unique mode of action and cellular location of the NR2B receptors in the CNS.
Keywords: nmda receptors, cns, neuropathologies, Ifenprodil
Current Medicinal Chemistry
Title: The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies
Volume: 11 Issue: 3
Author(s): Paul L. Chazot
Affiliation:
Keywords: nmda receptors, cns, neuropathologies, Ifenprodil
Abstract: The NMDAR2B subunit is the focus of increasing interest as a therapeutic target in a wide range of CNS pathologies, including acute and chronic pain, stroke and head trauma, drug-induced dyskinesias, and dementias. Due to significant pharmaceutical endeavor, an impressive collection of chemical leads has been developed which target the NR2B subunit, some of which appear to discriminate between closely related subtypes. We now have the benefit of a structural template for the ifenprodil binding site which should further improve future structure activity relationships. A growing appreciation of the likely extrasynaptic localisation of the NR2B receptor subtype and importance of NR2B protein modification, notably tyrosine phosphorylation, may explain its therapeutic importance. The apparent superior preclinical and clinical data for the second and third generation NR2B compounds is likely to reflect subtype selectivity, a unique mode of action and cellular location of the NR2B receptors in the CNS.
Export Options
About this article
Cite this article as:
Chazot L. Paul, The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies, Current Medicinal Chemistry 2004; 11 (3) . https://dx.doi.org/10.2174/0929867043456061
DOI https://dx.doi.org/10.2174/0929867043456061 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bipolar Affective Disorder in Young People: A Review
Adolescent Psychiatry Changing Faces of Transcriptional Regulation Reflected by Zic3
Current Genomics 3,4-Dihydroxyphenylacetaldehyde: A Potential Target for Neuroprotective Therapy in Parkinsons Disease
Current Drug Targets - CNS & Neurological Disorders Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Recent Developments in Studies of l-Stepholidine and its Analogs: Chemistry, Pharmacology and Clinical Implications
Current Medicinal Chemistry Novel Natural and Synthetic Ligands of the Endocannabinoid System
Current Medicinal Chemistry Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Breath Analysis: The Approach Towards Clinical Applications
Mini-Reviews in Medicinal Chemistry Role of the Central Cholinergic System in the Therapeutics of Schizophrenia
Current Neuropharmacology Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Evaluation of B Lymphocyte Deficiencies
Cardiovascular & Hematological Disorders-Drug Targets Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Pramipexole Tachyphylaxis and its Management in Bipolar Depression
Letters in Drug Design & Discovery Incomplete Coverage of Candidate Genes: A Poorly Considered Bias
Current Genomics Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?
Current Medicinal Chemistry Tremor and Rigidity in Patients with Parkinson’s Disease: Emphasis on Epidemiology, Pathophysiology and Contributing Factors
CNS & Neurological Disorders - Drug Targets Preface [Hot topic: Potential Therapeutic Agents for Parkinsons Disease (Executive Editor: Masato Asanuma)]
Current Pharmaceutical Design Adult Neural Stem Cell Therapy: Expansion In Vitro, Tracking In Vivo and Clinical Transplantation
Current Drug Targets